
Background and Purpose The neuropeptide calcitonin gene‐related peptide (CGRP) is a well‐established player in migraine. Current CGRP migraine therapeutics were designed to inhibit the canonical CGRP receptor, yet, based on in vitro studies, they can also inhibit to a lesser degree the amylin receptor 1 (AMY 1 ), which CGRP can also activate. This study explores the potential in vivo contributions of these receptors to migraine‐like symptoms in mice. Experimental Approach Receptor contributions were probed using light aversion as a surrogate for photophobia and diarrhoea as a readout for gastrointestinal dysfunction in outbred CD1 mice. Induction of diarrhoea was also measured in C57BL/6 J mice. CGRP and amylin were used as agonists, with two selective antagonists, olcegepant for the canonical CGRP receptor and AC187 for calcitonin receptor (CT)‐based receptors, including AMY 1 . Key Results CGRP and amylin induced light aversion in CD1 mice and diarrhoea in both strains. CGRP‐induced light aversion was partially rescued by AC187, but not olcegepant. Light aversion was fully rescued only by a combination of AC187 and olcegepant. In contrast, olcegepant fully blocked CGRP‐induced diarrhoea, while AC187 only partially blocked at high doses. As a control, olcegepant fully rescued CGRP‐induced periorbital touch hypersensitivity in CD1 mice. Conclusions and Implications More than one receptor contributes to CGRP‐induced light aversion, with a CT‐based receptor unexpectedly playing a major role. In contrast, the canonical CGRP receptor plays a major role in CGRP‐induced diarrhoea. Thus, targeting a CT‐based receptor may reduce photophobia with less adverse gastrointestinal effects in migraine patients.
There have been several step‐changes in asthma therapy, with the first being the use of inhaled short‐acting β 2 ‐agonists as bronchodilators and the introduction of inhaled corticosteroids (ICS) to reduce airway inflammation. The next revolution was the advent of inhaled combinations of long‐acting bronchodilators together with inhaled corticosteroids in the same inhalation device for improved asthma control. The most recent step‐change is the introduction of targeted monoclonal antibodies in patients with severe asthma and frequent exacerbations with biomarkers reflecting high levels of Type 2 (T2) inflammation. In chronic obstructive pulmonary disease (COPD), advances in bronchodilator therapy have been made, but limited advances in treating the inflammation and lung remodelling changes are present. We need new therapeutic agents for patients with a sub‐optimal response to current drugs. The aim of this narrative review is to provide a summary of the potential future anti‐inflammatory approaches undergoing testing for asthma and COPD rather than provide a systematic review. These approaches aim to optimize current treatment regimens and to develop novel agents against differing aspects of asthma and COPD pathophysiology. However, clinical trial results highlight our limited understanding of the biology of asthma and COPD subtypes. Furthermore, failed studies provide insight into disease pathophysiology and may indicate responder/non‐responder populations. Various aspects of cytokine‐ and environment‐activated intracellular pathways are being targeted. These include receptor agonists and antagonists and inhibitors of the Janus kinase (JAK) and Bruton tyrosine kinase (BTK) pathways for use against both stable disease and for reducing disease exacerbations or ‘attacks’. New or better use of current biomarkers will provide non‐invasive means of patients most likely to respond to any one specific or combination of drugs.
Abstract Background and Purpose Ionising radiation (IR) is a major cancer‐treatment modality, yet the mechanisms driving IR‐triggered cardiovascular injury are poorly defined. This work aimed to uncover how IR accelerates atherosclerosis (AS) and the underlying molecular mechanisms. Experimental Approach We applied 9.4 T magnetic resonance imaging to evaluate atherosclerotic lesions. Single‐cell RNA sequencing was performed on carotid arteries. Apolipoprotein E (ApoE) knockout mice with caspase‐1 deletion and macrophage‐specific cGAS knockdown were used for in vivo validation. JASPAR prediction and dual‐luciferase reporter assays were implemented to verify transcriptional regulation of NLRP3. Key Results IR substantially aggravated atherosclerotic progression, accompanied by elevated pyroptosis‐related gene expression in macrophages within atherosclerotic plaques. Mechanistically, IR promoted cytoplasmic mtDNA release to activate the cGAS/STING/TBK1 axis and cause p‐IRF3 nuclear translocation. Phosphorylated IRF3 bound to the NLRP3 promoter and enhanced its transcription. Genetic ablation of caspase‐1 or macrophage‐specific cGAS knockdown alleviated IR‐driven AS progression. Conclusions and Implications Macrophage pyroptosis drives IR‐accelerated AS progression through the mtDNA/cGAS/STING/p‐IRF3 axis‐dependent transcriptional up‐regulation of NLRP3. Targeting the cGAS‐STING pathway may provide a therapeutic strategy for IR‐associated atherosclerotic plaque progression.